TCS 2510

TCS 2510 is a selective EP4 agonist. TCS 2510 can be used for the research of metabolic diseases^[1]. IC50 & Target: EP4^[1] In Vitro: TCS 2510 (0.001~100 μM; GLUTag cells) stimulates glucagon like peptide 1 secretion. TCS2510 activates the Gas signaling pathway. TCS 2510 (10 μM; 2~24 h; GLUTag cells) increases the Gcg mRNA expression levels. TCS 2510 produces a concentration dependent increase in cAMP levels in GLUTag cells with EC₅₀ of 20 nM and the maximal stimulation of 60 % over the basal cAMP levels. The decrease in cell impedance in GLUTag cells observed with TCS 2510 is concentration dependent with IC₅₀ of 15 nM. TCS 2510 produces a concentration-dependent increase in glucagon like peptide 2 secretion in GLUTag cells^[1]. In Vivo: TCS 2510 (0.1~10 mg/kg; p.o.) produces a dose-dependent elevation in plasma glucagon like peptide 1 levels in fasted mice measured 15 min after compound administration^[1].
TCS 2510 (10 mg/kg; p.o.) increases plasma glucagon like peptide 1 levels up to 8-fold over the basal hormone levels^[1].
TCS 2510 (1~10 mg/kg; p.o) affords a significant elevation in plasma glucagon like peptide 2 levels^[1]